Regulatory FDA kicks off review of Roche’s Gazyva for wider lupus use PharmaphorumRoche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.RegulatoryImmunology & InflammationRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus. RegulatoryImmunology & InflammationRead full story Post navigation Previous: Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapyNext: Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026